captopril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
angiotensin-converting enzyme inhibitors 484 62571-86-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • captopril
  • (-)-Captopril
  • L-Captopril
  • lopirin
  • S-Captopril
  • SQ14225
  • SQ-14225
  • SQ 14225
A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.
  • Molecular weight: 217.28
  • Formula: C9H15NO3S
  • CLOGP: 0.89
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 57.61
  • ALOGS: -1.68
  • ROTB: 3
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 160 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 38 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 19.72 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 69 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.75 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 12 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.73 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -2.683 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.735 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.834 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 3.006 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 73 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 56.240 % High 1
herg hERG pIC50 4.150 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.663 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.606 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 62.130 % High 1
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,KDR,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70 42
kinase-selectivity-class ACVR2B,AXL,BRAF,CDK9,EIF2AK3,EPHB4,GRK2,MAP2K6,MAPK7,PIK3CD,PRKDC,STK33,TEK,TGFBR1 14
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.403 High 1
mh-clint Mouse hepatocyte intrinsic clearance 5.821 High 1
mppb Mouse plasma protein binding (% unbound) 93.460 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.272 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 74.210 % High 1
rh-clint Rat hepatocyte intrinsic clearance 1.390 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 95.230 % High 1
rppb Rat plasma protein binding (% unbound) 71.670 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 810.961 uM High 1

Approvals:

DateAgencyCompanyOrphan
April 6, 1981 FDA PAR PHARM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Segmental diverticular colitis 101.32 15.32 18 12396 156 90615877
Pedal pulse abnormal 96.78 15.32 18 12396 206 90615827
Cardiac failure congestive 94.37 15.32 90 12324 98604 90517429
Toxic epidermal necrolysis 90.31 15.32 56 12358 32472 90583561
Calcium ionised decreased 87.87 15.32 18 12396 350 90615683
Reduced facial expression 86.40 15.32 26 12388 2527 90613506
Blood pressure abnormal 76.16 15.32 42 12372 19603 90596430
Listless 72.17 15.32 24 12390 3225 90612808
Restlessness 71.19 15.32 50 12364 35670 90580363
Feeding intolerance 69.71 15.32 18 12396 996 90615037
Insulin autoimmune syndrome 69.25 15.32 13 12401 157 90615876
Hyponatraemia 67.16 15.32 87 12327 133451 90482582
Head discomfort 66.30 15.32 36 12378 16297 90599736
Multiple organ dysfunction syndrome 64.69 15.32 62 12352 68274 90547759
Dermatitis exfoliative 63.17 15.32 25 12389 5511 90610522
Dehydration 57.82 15.32 99 12315 194348 90421685
Apathy 52.36 15.32 27 12387 11013 90605020
Myocardial infarction 51.64 15.32 68 12346 105904 90510129
Left ventricular hypertrophy 50.66 15.32 22 12392 6122 90609911
Foreign body 49.78 15.32 17 12397 2477 90613556
Self-injurious ideation 49.31 15.32 18 12396 3185 90612848
Prescription drug used without a prescription 49.02 15.32 18 12396 3237 90612796
Drug interaction 48.64 15.32 113 12301 276340 90339693
Hyperthyroidism 46.99 15.32 30 12384 18280 90597753
Cardiac failure 46.90 15.32 66 12348 109430 90506603
Atrial fibrillation 45.04 15.32 72 12342 133539 90482494
Labile hypertension 44.62 15.32 11 12403 504 90615529
Electrolyte imbalance 44.45 15.32 32 12382 23713 90592320
Immobile 43.45 15.32 20 12394 6378 90609655
Gastrointestinal sounds abnormal 43.20 15.32 18 12396 4525 90611508
Haemodynamic instability 42.50 15.32 24 12390 11715 90604318
Hypokalaemia 41.94 15.32 69 12345 131047 90484986
Renal failure 39.31 15.32 67 12347 130940 90485093
Cholecystitis 39.03 15.32 26 12388 17014 90599019
Systemic lupus erythematosus 38.25 15.32 3 12411 361893 90254140
Joint swelling 37.89 15.32 11 12403 503289 90112744
Infusion related reaction 37.68 15.32 6 12408 416774 90199259
Cognitive disorder 37.68 15.32 47 12367 69360 90546673
Affect lability 37.65 15.32 26 12388 18037 90597996
Hypotension 35.95 15.32 112 12302 325285 90290748
Urinary retention 35.24 15.32 34 12380 37710 90578323
Abdominal discomfort 34.90 15.32 11 12403 477317 90138716
Blood urea increased 33.42 15.32 30 12384 30383 90585650
Acute kidney injury 32.41 15.32 107 12307 320280 90295753
Acute myocardial infarction 31.77 15.32 31 12383 34859 90581174
Skin test positive 29.74 15.32 9 12405 891 90615142
Pelvic fracture 29.61 15.32 21 12393 15198 90600835
Encephalopathy 29.38 15.32 34 12380 46410 90569623
Cholelithiasis 29.21 15.32 36 12378 52470 90563563
Metabolic acidosis 29.10 15.32 37 12377 55639 90560394
Bedridden 28.95 15.32 19 12395 12129 90603904
Hypertensive crisis 28.87 15.32 22 12392 17762 90598271
Stomatitis 27.09 15.32 3 12411 274695 90341338
Maternal exposure during pregnancy 26.84 15.32 8 12406 360055 90255978
Circulatory collapse 26.25 15.32 24 12390 24880 90591153
Abnormal behaviour 26.21 15.32 23 12391 22605 90593428
Scleroderma renal crisis 26.16 15.32 7 12407 445 90615588
Alopecia 26.04 15.32 18 12396 495053 90120980
Blood sodium decreased 26.01 15.32 25 12389 27588 90588445
Coronary artery disease 25.38 15.32 27 12387 33596 90582437
Therapeutic product effect decreased 25.06 15.32 4 12410 277567 90338466
Cyanosis 25.03 15.32 21 12393 19434 90596599
Fatigue 24.53 15.32 79 12335 1153944 89462089
Renal injury 24.36 15.32 16 12398 10227 90605806
Pain 24.22 15.32 64 12350 996277 89619756
Arthropathy 24.10 15.32 10 12404 366232 90249801
Hypoacusis 23.97 15.32 24 12390 27826 90588207
Occupational exposure to product 23.97 15.32 10 12404 2521 90613512
Vascular stent thrombosis 23.82 15.32 8 12406 1108 90614925
Rheumatoid arthritis 23.71 15.32 10 12404 362604 90253429
Sudden death 23.44 15.32 16 12398 10893 90605140
Respiratory disorder 23.31 15.32 36 12378 64780 90551253
Hyperkalaemia 23.24 15.32 36 12378 64928 90551105
Cross sensitivity reaction 22.80 15.32 10 12404 2847 90613186
Bradycardia 22.69 15.32 41 12373 83806 90532227
Nasopharyngitis 22.49 15.32 14 12400 407090 90208943
Oxygen saturation decreased 22.32 15.32 47 12367 107436 90508597
Blood potassium decreased 22.27 15.32 30 12384 47697 90568336
Cerebrovascular accident 22.23 15.32 51 12363 123482 90492551
Blood pressure decreased 22.05 15.32 38 12376 74857 90541176
Hepatic enzyme increased 21.95 15.32 11 12403 360725 90255308
Electrocardiogram abnormal 21.88 15.32 15 12399 10283 90605750
Blood creatinine increased 21.83 15.32 45 12369 101341 90514692
Lower respiratory tract infection 21.77 15.32 4 12410 250655 90365378
Sinusitis 21.58 15.32 10 12404 343078 90272955
Swelling 21.03 15.32 16 12398 419042 90196991
Contraindicated product administered 20.65 15.32 9 12405 320130 90295903
Nodal rhythm 20.01 15.32 8 12406 1810 90614223
Cardiac failure acute 19.90 15.32 15 12399 11914 90604119
Cardio-respiratory arrest 19.86 15.32 33 12381 63107 90552926
Arthralgia 19.67 15.32 49 12365 778473 89837560
Musculoskeletal stiffness 19.66 15.32 8 12406 296524 90319509
Renal impairment 19.50 15.32 44 12370 105377 90510656
Stevens-Johnson syndrome 19.41 15.32 22 12392 29354 90586679
Elastosis perforans 19.29 15.32 3 12411 10 90616023
Angiopathy 19.29 15.32 11 12403 5469 90610564
Lymphocytosis 19.20 15.32 9 12405 2988 90613045
Psoriatic arthropathy 19.08 15.32 4 12410 228331 90387702
Extrasystoles 18.96 15.32 11 12403 5646 90610387
Posterior reversible encephalopathy syndrome 18.77 15.32 19 12395 22320 90593713
Vertigo 18.72 15.32 34 12380 69777 90546256
Respiratory failure 18.21 15.32 46 12368 118372 90497661
Dermatitis contact 18.16 15.32 15 12399 13580 90602453
Artery dissection 17.71 15.32 4 12410 125 90615908
Off label use 17.33 15.32 85 12329 1102167 89513866
Sinus bradycardia 17.21 15.32 16 12398 16936 90599097
Poor quality sleep 17.18 15.32 19 12395 24674 90591359
Syncope 16.83 15.32 48 12366 132615 90483418
Migraine 16.61 15.32 3 12411 190389 90425644
Delirium 16.52 15.32 41 12373 104318 90511715
Wheezing 16.48 15.32 6 12408 238074 90377959
Shock 16.43 15.32 20 12394 28758 90587275
Progressive supranuclear palsy 16.40 15.32 4 12410 175 90615858
Cardiac arrest 16.38 15.32 41 12373 104894 90511139
Potentiating drug interaction 16.35 15.32 10 12404 5652 90610381
Ill-defined disorder 15.95 15.32 3 12411 184888 90431145
Dry mouth 15.85 15.32 3 12411 184056 90431977
Occupational dermatitis 15.50 15.32 3 12411 43 90615990
Ventricular tachycardia 15.47 15.32 18 12396 24690 90591343

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cyanosis 46.86 14.92 33 9159 14998 42597145
Angioedema 39.09 14.92 47 9145 42430 42569713
Blood ketone body increased 34.69 14.92 10 9182 528 42611615
Hypokalaemia 32.91 14.92 57 9135 71664 42540479
Scleroderma renal crisis 32.23 14.92 9 9183 423 42611720
Klebsiella infection 31.03 14.92 23 9169 11309 42600834
Cardiac failure congestive 30.47 14.92 61 9131 85541 42526602
Myocardial infarction 30.25 14.92 76 9116 123933 42488210
Renal failure 27.94 14.92 81 9111 143645 42468498
Kidney small 24.56 14.92 5 9187 58 42612085
Hypertensive crisis 24.17 14.92 19 9173 10187 42601956
Oral mucosal exfoliation 23.39 14.92 6 9186 203 42611940
Cerebrovascular accident 23.11 14.92 59 9133 97101 42515042
Perioral dermatitis 22.67 14.92 6 9186 230 42611913
Coronary artery disease 22.45 14.92 41 9151 53679 42558464
Blood creatinine increased 22.34 14.92 63 9129 109940 42502203
Hirsutism 21.57 14.92 6 9186 278 42611865
Gingival oedema 20.67 14.92 4 9188 35 42612108
Long QT syndrome 20.26 14.92 11 9181 3156 42608987
Gingival hypertrophy 19.98 14.92 10 9182 2429 42609714
Off label use 19.90 14.92 71 9121 638264 41973879
Indifference 19.67 14.92 5 9187 163 42611980
Pulmonary hypertensive crisis 18.62 14.92 5 9187 203 42611940
Hypotension 18.17 14.92 106 9086 257525 42354618
Pulmonary hypoplasia 18.06 14.92 6 9186 508 42611635
Vascular resistance systemic decreased 16.99 14.92 4 9188 94 42612049
Reaction to excipient 16.57 14.92 6 9186 656 42611487
Loss of consciousness 15.99 14.92 50 9142 92304 42519839
Arrhythmia 15.87 14.92 30 9162 40287 42571856
Renal impairment 15.81 14.92 56 9136 110172 42501971
Vitamin B12 deficiency 15.79 14.92 11 9181 4911 42607232
Renal failure neonatal 15.66 14.92 4 9188 133 42612010
Cardiac failure 15.08 14.92 54 9138 106802 42505341

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiac failure congestive 110.30 13.65 133 18926 150867 110419373
Segmental diverticular colitis 97.19 13.65 18 19041 156 110570084
Pedal pulse abnormal 90.83 13.65 18 19041 230 110570010
Myocardial infarction 82.55 13.65 131 18928 191952 110378288
Calcium ionised decreased 73.12 13.65 18 19041 648 110569592
Cyanosis 66.80 13.65 49 19010 29692 110540548
Toxic epidermal necrolysis 64.23 13.65 63 18996 56664 110513576
Reduced facial expression 64.04 13.65 24 19035 3627 110566613
Feeding intolerance 62.85 13.65 18 19041 1166 110569074
Renal failure 60.86 13.65 126 18933 226448 110343792
Hyponatraemia 59.59 13.65 122 18937 217531 110352709
Dermatitis exfoliative 53.89 13.65 30 19029 11317 110558923
Hypokalaemia 53.19 13.65 105 18954 182343 110387897
Drug interaction 52.35 13.65 197 18862 499986 110070254
Cardiac failure 52.33 13.65 106 18953 187520 110382720
Listless 52.31 13.65 22 19037 4493 110565747
Restlessness 51.96 13.65 56 19003 56203 110514037
Head discomfort 51.22 13.65 35 19024 18965 110551275
Hypotension 49.68 13.65 200 18859 523649 110046591
Scleroderma renal crisis 48.85 13.65 14 19045 909 110569331
Apathy 48.79 13.65 32 19027 16207 110554033
Blood pressure abnormal 48.23 13.65 36 19023 22388 110547852
Insulin autoimmune syndrome 47.21 13.65 13 19046 729 110569511
Hypertensive crisis 45.57 13.65 36 19023 24336 110545904
Cerebrovascular accident 45.39 13.65 98 18961 181186 110389054
Joint swelling 44.13 13.65 11 19048 442834 110127406
Coronary artery disease 44.10 13.65 58 19001 71632 110498608
Self-injurious ideation 43.19 13.65 19 19040 4327 110565913
Angioedema 42.03 13.65 67 18992 98433 110471807
Multiple organ dysfunction syndrome 41.45 13.65 85 18974 151625 110418615
Labile hypertension 40.46 13.65 11 19048 588 110569652
Blood creatinine increased 40.34 13.65 94 18965 182795 110387445
Gastrointestinal sounds abnormal 40.23 13.65 20 19039 5998 110564242
Foreign body 39.47 13.65 16 19043 2979 110567261
Off label use 38.91 13.65 131 18928 1500054 109070186
Dehydration 38.76 13.65 121 18938 279390 110290850
Klebsiella infection 36.22 13.65 29 19030 19980 110550260
Electrolyte imbalance 36.21 13.65 38 19021 36990 110533250
Prescription drug used without a prescription 35.96 13.65 18 19041 5478 110564762
Infusion related reaction 33.37 13.65 12 19047 381150 110189090
Acute myocardial infarction 33.04 13.65 55 19004 83722 110486518
Immobile 32.90 13.65 19 19040 7683 110562557
Occupational exposure to product 32.51 13.65 10 19049 829 110569411
Abdominal discomfort 31.85 13.65 14 19045 393844 110176396
Atrial fibrillation 31.44 13.65 99 18960 229543 110340697
Renal impairment 31.28 13.65 87 18972 188358 110381882
Lower respiratory tract infection 31.03 13.65 3 19056 243103 110327137
Hyperthyroidism 30.36 13.65 31 19028 29230 110541010
Wound 29.64 13.65 3 19056 234434 110335806
Bradycardia 29.04 13.65 75 18984 155442 110414798
Nasopharyngitis 28.89 13.65 16 19043 394345 110175895
Rheumatoid arthritis 28.77 13.65 8 19051 299605 110270635
Cholecystitis 27.91 13.65 28 19031 25854 110544386
Left ventricular hypertrophy 27.90 13.65 21 19038 13223 110557017
Blood ketone body increased 27.82 13.65 9 19050 879 110569361
Affect lability 27.49 13.65 24 19035 18613 110551627
Loss of consciousness 27.21 13.65 85 18974 196221 110374019
Blood urea increased 27.12 13.65 40 19019 54917 110515323
Pelvic fracture 26.66 13.65 21 19038 14133 110556107
Cognitive disorder 26.25 13.65 51 19008 87460 110482780
Pulmonary hypoplasia 26.09 13.65 5 19054 53 110570187
Maternal exposure during pregnancy 26.02 13.65 6 19053 254877 110315363
Cholelithiasis 25.49 13.65 42 19017 63380 110506860
Bedridden 25.46 13.65 20 19039 13405 110556835
Gingival hypertrophy 24.90 13.65 13 19046 4318 110565922
Alopecia 23.69 13.65 17 19042 364736 110205504
Drug reaction with eosinophilia and systemic symptoms 23.60 13.65 47 19012 82048 110488192
Pulmonary oedema 23.57 13.65 53 19006 100606 110469634
Skin test positive 23.51 13.65 9 19050 1440 110568800
Renal injury 23.48 13.65 22 19037 18691 110551549
Fatigue 23.44 13.65 119 18940 1215839 109354401
Posterior reversible encephalopathy syndrome 23.35 13.65 29 19030 33832 110536408
Arrhythmia 22.66 13.65 42 19017 69533 110500707
Rhabdomyolysis 22.41 13.65 58 19001 120343 110449897
Completed suicide 22.30 13.65 7 19052 242374 110327866
Cross sensitivity reaction 21.85 13.65 13 19046 5554 110564686
Laryngeal oedema 21.66 13.65 16 19043 9791 110560449
Impaired healing 21.38 13.65 4 19055 196713 110373527
Indifference 21.28 13.65 6 19053 367 110569873
Cardio-respiratory arrest 20.74 13.65 55 19004 115781 110454459
Arthropathy 20.57 13.65 12 19047 287510 110282730
Sinusitis 20.37 13.65 13 19046 296675 110273565
Oligohydramnios 20.18 13.65 11 19048 3983 110566257
COVID-19 treatment 20.00 13.65 6 19053 457 110569783
Ventricular extrasystoles 19.96 13.65 22 19037 22619 110547621
Haemodynamic instability 19.77 13.65 22 19037 22866 110547374
Stomatitis 19.73 13.65 11 19048 270231 110300009
Lactic acidosis 19.68 13.65 47 19012 92764 110477476
Syncope 19.67 13.65 78 18981 202458 110367782
Swelling 19.54 13.65 19 19040 351022 110219218
Blood potassium decreased 19.32 13.65 34 19025 54080 110516160
Therapeutic product effect decreased 19.25 13.65 9 19050 244307 110325933
Blood potassium increased 19.06 13.65 26 19033 33223 110537017
Long QT syndrome 18.92 13.65 13 19046 7105 110563135
Pain 18.63 13.65 93 18966 954862 109615378
Kidney small 18.53 13.65 5 19054 260 110569980
Elastosis perforans 18.38 13.65 3 19056 11 110570229
Drug intolerance 18.34 13.65 26 19033 406486 110163754
Musculoskeletal stiffness 18.22 13.65 13 19046 279809 110290431
Arthralgia 18.18 13.65 71 18988 779561 109790679
Acute kidney injury 18.10 13.65 178 18881 635252 109934988
Hyperkalaemia 18.07 13.65 58 19001 135738 110434502
Circulatory collapse 17.99 13.65 29 19030 42964 110527276
Treatment failure 17.89 13.65 13 19046 277221 110293019
Wheezing 17.77 13.65 11 19048 255219 110315021
Migraine 17.60 13.65 4 19055 171648 110398592
Pulmonary hypertension 17.57 13.65 33 19026 55187 110515053
Psoriatic arthropathy 17.54 13.65 6 19053 196755 110373485
Gingival oedema 17.39 13.65 4 19055 107 110570133
Perioral dermatitis 17.39 13.65 6 19053 715 110569525
Cardiac failure acute 17.21 13.65 21 19038 24057 110546183
Tongue oedema 17.19 13.65 13 19046 8243 110561997
Respiratory disorder 17.18 13.65 38 19021 71344 110498896
Extrasystoles 17.10 13.65 13 19046 8305 110561935
Blood pressure decreased 17.02 13.65 51 19008 115040 110455200
Angiopathy 16.54 13.65 13 19046 8717 110561523
Hyperplasia 16.27 13.65 7 19052 1511 110568729
Nodal rhythm 16.12 13.65 9 19050 3414 110566826
Abnormal behaviour 15.89 13.65 26 19033 39013 110531227
Apraxia 15.83 13.65 9 19050 3531 110566709
Pulmonary hypertensive crisis 15.83 13.65 5 19054 452 110569788
Respiratory failure 15.63 13.65 76 18983 215256 110354984
Haemorrhagic necrotic pancreatitis 15.54 13.65 4 19055 173 110570067
Hypoacusis 15.09 13.65 24 19035 35167 110535073
Hepatic enzyme increased 14.99 13.65 20 19039 320872 110249368
Blood sodium decreased 14.89 13.65 25 19034 38294 110531946
Injection site pain 14.89 13.65 6 19053 177916 110392324
Oxygen saturation decreased 14.87 13.65 60 18999 156922 110413318
Dermatitis contact 14.87 13.65 15 19044 13938 110556302
Dry mouth 14.80 13.65 8 19051 199940 110370300
Progressive supranuclear palsy 14.60 13.65 4 19055 220 110570020
Shock 14.59 13.65 30 19029 53558 110516682
Metabolic acidosis 14.56 13.65 44 19015 99700 110470540
Vascular stent thrombosis 14.49 13.65 9 19050 4152 110566088
Intentional product use issue 14.28 13.65 13 19046 247893 110322347
Encephalopathy 14.01 13.65 38 19021 81017 110489223
Vascular resistance systemic decreased 13.92 13.65 4 19055 262 110569978
Orthopnoea 13.91 13.65 13 19046 11008 110559232
Sudden death 13.87 13.65 19 19040 24376 110545864
Localised oedema 13.85 13.65 12 19047 9211 110561029
Hyperglycaemia 13.83 13.65 39 19020 85051 110485189
Respiratory distress 13.66 13.65 34 19025 68840 110501400

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C09AA01 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, PLAIN
ACE inhibitors, plain
ATC C09BA01 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and diuretics
FDA MoA N0000000181 Angiotensin-converting Enzyme Inhibitors
FDA EPC N0000175562 Angiotensin Converting Enzyme Inhibitor
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:35457 EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:233423 antifibrotic agent
MeSH PA D000806 Angiotensin-Converting Enzyme Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors

Related Drugs by ATC class:

C09AA ACE inhibitors, plain 15 drugs
benazeprilcilazaprildelaprilenalaprilfosinoprilimidaprillisinoprilmoexiprilperindoprilquinaprilramiprilspirapril show all 15 →
C09BA ACE inhibitors and diuretics 11 drugs
benazeprilcilazaprildelaprilenalaprilfosinoprillisinoprilmoexiprilperindoprilquinaprilramiprilzofenopril

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Chronic heart failure indication 48447003
Diabetic renal disease indication 127013003
Left ventricular cardiac dysfunction indication 429589006
Atrial fibrillation off-label use 49436004 DOID:0060224
Cystinuria off-label use 85020001 DOID:9266
Diastolic heart failure off-label use 418304008 DOID:9775
Cystine Renal Calculi off-label use
Nondiabetic Proteinuric Nephropathy off-label use
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Secondary angle-closure glaucoma contraindication 21571006
Hypovolemia contraindication 28560003
Acute cerebrovascular insufficiency contraindication 29322000
Dehydration contraindication 34095006
Hyperuricemia contraindication 35885006 DOID:1920
Immunosuppression contraindication 38013005
Angioedema contraindication 41291007 DOID:1558
Hypokalemia contraindication 43339004
Low blood pressure contraindication 45007003
Cough contraindication 49727002
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Aortic valve stenosis contraindication 60573004 DOID:1712
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Transplantation contraindication 77465005
Hereditary angioneurotic edema contraindication 82966003 DOID:14735
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Disorder of connective tissue contraindication 105969002 DOID:65
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Hypertrophic cardiomyopathy contraindication 233873004 DOID:11984
Disease of liver contraindication 235856003 DOID:409
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Renal artery stenosis contraindication 302233006
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Azotemia contraindication 445009001
Hemodialysis with High-Flux Membrane contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.85 acidic
pKa2 9.56 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Angiotensin-converting enzyme Enzyme INHIBITOR Ki 8.70 WOMBAT-PK CHEMBL
Prostaglandin G/H synthase 1 Enzyme Ki 4.77 CHEMBL
Prothrombin Enzyme Ki 7.32 CHEMBL
Renin Enzyme Ki 8.77 CHEMBL
Leukotriene A-4 hydrolase Enzyme IC50 7.15 CHEMBL
Prostaglandin G/H synthase 2 Enzyme Ki 4.92 CHEMBL
Angiotensin-converting enzyme Enzyme Ki 8.77 CHEMBL
Angiotensin-converting enzyme Enzyme Ki 8.70 CHEMBL
Succinyl-diaminopimelate desuccinylase Enzyme Ki 5.74 CHEMBL
Beta-lactamase Enzyme Ki 5.62 CHEMBL
Beta-lactamase II Enzyme Ki 4.75 CHEMBL
Beta-lactamase class B VIM-2 Enzyme Kd 6.22 CHEMBL
Beta-lactamase NDM-1 Enzyme Kd 4.85 CHEMBL

External reference:

IDSource
4017614 VUID
N0000145994 NUI
D00251 KEGG_DRUG
1998 RXNORM
C0006938 UMLSCUI
CHEBI:3380 CHEBI
X8Z PDB_CHEM_ID
CHEMBL1560 ChEMBL_ID
DB01197 DRUGBANK_ID
D002216 MESH_DESCRIPTOR_UI
44093 PUBCHEM_CID
5158 IUPHAR_LIGAND_ID
4373 INN_ID
9G64RSX1XD UNII
4347 MMSL
455 MMSL
d00006 MMSL
29439004 SNOMEDCT_US
387160004 SNOMEDCT_US
4017614 VANDF
000656 NDDF
9G64RSX1XD INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0143-1171 TABLET 12.50 mg ORAL ANDA 22 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0143-1172 TABLET 25 mg ORAL ANDA 22 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0143-1173 TABLET 50 mg ORAL ANDA 22 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0143-1174 TABLET 100 mg ORAL ANDA 22 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0904-7105 TABLET 12.50 mg ORAL ANDA 12 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 0904-7106 TABLET 25 mg ORAL ANDA 12 sections
captopril HUMAN PRESCRIPTION DRUG LABEL 1 10135-791 TABLET 12.50 mg ORAL ANDA 25 sections
captopril HUMAN PRESCRIPTION DRUG LABEL 1 10135-792 TABLET 25 mg ORAL ANDA 25 sections
captopril HUMAN PRESCRIPTION DRUG LABEL 1 10135-793 TABLET 50 mg ORAL ANDA 25 sections
CAPTOPRIL HUMAN PRESCRIPTION DRUG LABEL 1 10544-175 TABLET 50 mg ORAL ANDA 19 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 11788-135 TABLET 12.50 mg ORAL ANDA 22 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 11788-136 TABLET 25 mg ORAL ANDA 22 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 11788-137 TABLET 50 mg ORAL ANDA 22 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 11788-138 TABLET 100 mg ORAL ANDA 22 sections
CAPTOPRIL AND HYDROCHLOROTHIAZIDE Human Prescription Drug Label 2 16571-827 TABLET 25 mg ORAL ANDA 22 sections
CAPTOPRIL AND HYDROCHLOROTHIAZIDE Human Prescription Drug Label 2 16571-828 TABLET 25 mg ORAL ANDA 22 sections
CAPTOPRIL AND HYDROCHLOROTHIAZIDE Human Prescription Drug Label 2 16571-829 TABLET 50 mg ORAL ANDA 22 sections
CAPTOPRIL AND HYDROCHLOROTHIAZIDE Human Prescription Drug Label 2 16571-830 TABLET 50 mg ORAL ANDA 22 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 21695-477 TABLET 25 mg ORAL ANDA 24 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 21695-478 TABLET 50 mg ORAL ANDA 24 sections
Captopril Human Prescription Drug Label 1 27241-160 TABLET 12.50 mg ORAL ANDA 12 sections
Captopril Human Prescription Drug Label 1 27241-161 TABLET 25 mg ORAL ANDA 12 sections
Captopril Human Prescription Drug Label 1 27241-162 TABLET 50 mg ORAL ANDA 12 sections
Captopril Human Prescription Drug Label 1 27241-163 TABLET 100 mg ORAL ANDA 12 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 31722-141 TABLET 12.50 mg ORAL ANDA 24 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 31722-142 TABLET 25 mg ORAL ANDA 24 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 31722-143 TABLET 50 mg ORAL ANDA 24 sections
Captopril HUMAN PRESCRIPTION DRUG LABEL 1 31722-144 TABLET 100 mg ORAL ANDA 24 sections
CAPTOPRIL HUMAN PRESCRIPTION DRUG LABEL 1 33261-182 TABLET 50 mg ORAL ANDA 19 sections
CAPTOPRIL HUMAN PRESCRIPTION DRUG LABEL 1 33261-536 TABLET 100 mg ORAL ANDA 19 sections